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Acquired hemophilia A (AHA) is a very rare disease, caused by the development of autoantibodies, directed against circulating
factor VIII of coagulation. Age distribution is bimodal, with a ﬁrstpeak occurring among young women in the postpartumperiod,
and a second major peak of incidence among elderly patients in whom it is frequently associated with malignancy and drugs.
This disease often represents a life-threatening bleeding condition, especially in the elderly, thus requiring a prompt therapeutic
intervention, including control of acute bleeding and eradication of the inhibitor by immunosuppressive therapy. The diagnosis
of AHA should be considered in any elderly patient who presents with bleeding and prolonged activated Partial Thromboplastin
Time. Moreover, the coexistence of a series of underlying diseases associated with AHA should be always searched for. An early
recognition and an adequate treatment of this coagulation disorder and of the possible associated diseases play a signiﬁcant
role for a favourable outcome, but concomitant morbidities in the elderly may limit aggressive therapy and may complicate the
clinical scenario. We report 3 consecutive elderly patients successfully treated with recombinant activated factor VII and standard
immunosuppressive regimens, with remission of the disease.
1.Introduction
AcquiredhaemophiliaA(AHA)isaveryraredisease,withan
estimated annual incidence between 1.3 and 1.5 per million
per year [1–6]. This potentially life-threatening bleeding
disorder is caused by the development of autoantibodies,
generally IgGk4, directed against circulating factor VIII
(FVIII) of coagulation. Age distribution is bimodal, with a
ﬁrst peak occurring among young adults, due to cases in
women in the postpartum period, and a second major peak
in elderly patients in whom it is frequently associated with
malignancy and drugs, and very diﬃcult to manage due to
the comorbidities and the “fragility” of the older subjects
[7]. Other associated conditions are: autoimmune disorders,
hematologic malignancies, inﬂammatory bowel diseases,
dermatologic disorders, respiratory diseases, diabetes mel-
litus, and hepatitis B and C infections. The treatment of
the underlying diseases often eradicates the coagulation
autoantibodies [1–6, 8]. In most patients, however, FVIII
autoantibodies are idiopathic [1–6].
The pattern of bleeding in AHA diﬀers from that in
congenital haemophilia A. Bleeding tends to occur in soft
tissue, muscle, retroperitoneal space, and gastrointestinal
or genitourinary tracts. In contrast with patients with
congenital haemophilia A, patients with haemarthroses are
rare. Iatrogenic bleeding is also common. Rates of mortality
from acquired haemophilia up to 44% have been reported,
with most deaths occurring in the ﬁrst few weeks [6]. Thus
a prompt recognition of this disorder and an early and
aggressive treatment are mandatory, as diagnostic delays or
inadequate treatments are associated with high mortality
rates.
Diagnosis may be challenging, since the patient will have
nopersonalorfamilyhistoryofbleedingdisorders.However,
in any patient who presents with recently-onset severe or
deep tissue bleeding and an unexplained isolated prolonged
activated Partial Thromboplastin Time (aPTT), AHA should
be considered [1–6]( Table 1). The presence of circulating
inhibitors is conﬁrmed by the mixing test, showing the lack
ofcorrectionoftheaPTTwhenamixtureofequalvolumesof2 Current Gerontology and Geriatrics Research
Table 1: Diagnosis of AHA in the elderly (see [5] by Huth-Kuhne
et al.).
The diagnosis of AHA should be considered in the presence of
both
(1) acute/recent bleeding in elderly patients with no previous
history of bleeding,
(2) unexplained isolated aPTT
patient and normal plasma is incubated at 37
◦ for 2 hours or
longer.AnisolatedlowFVIII:ClevelissuggestiveofAHA[1–
6, 9]. The diagnosis is then conﬁrmed by a Bethesda positive
assayforFVIIIinhibitortitre:1BethesdaUnit(BU)/mListhe
quantity of inhibitor that neutralizes 50% of clotting factor
activity in normal plasma) [1–6, 9]. In most cases, however,
the bleeding phenotype does not correlate with laboratory
assessment (FVIII level and inhibitor titre) [1–6].
Treatment of AHA focuses on 2 goals: control of acute
bleeding and immunosuppressive therapy to eradicate FVIII
inhibitors. Acute bleeding episodes are usually treated with
bypassing agents and good eﬃcacy is seen with both recom-
binant activated (rFVIIa) and activated prothrombin com-
plex concentrates (aPCCs). Eradication of the autoimmune
inhibitor antibody with immunosuppression is indicated
as soon as the diagnosis has been conﬁrmed, because
patients remain at risk of potentially fatal bleeding until the
inhibitor is suppressed. Steroids, alone or in combination
with cyclophosphamide or azathioprine, induce remission
in about 70% of the patients. [1–6]. In nonresponders,
alternative approaches have been proposed, in particular,
using rituximab [4, 10–14]. This chimeric human/mouse
monoclonalantibodydirectedattheCD20antigenexpressed
in mature-B and pre-B lymphocytes induces B-cell depletion
rapidly and completely. However, disease activity has been
seentorecuratthetimeofB-cellrepopulation,soreteatment
is usually necessary. Outcomes and adverse eﬀects of long-
term B-cell depletion are unknown, so caution should be
eserted, especially in patients with a good prognosis [14, 15].
We report clinical features and treatment of three
patients with a history of bleeding occurring in the elderly
in whom AHA was diagnosed.
2.CaseReports
Case 1. A 70-year-old man presented with large posttrau-
matic left leg haematoma. The patient had a history of
coronary heart disease (acute myocardial infarction treated
with percutaneous transluminal coronary angioplasty and
stenting, 10 years earlier), therefore he was on chronic
antiplatelet treatment (aspirin 100mg/day). About 3 years
earlier, because of haematuria, he performed an abdominal
ultrasonography (US) that revealed a renal mass conﬁrmed
at computed tomography (CT) scan, but the patient did
not perform further controls. As gastrointestinal bleeding
(melena, due to multiple peptic ulcers) occurred one year
earlier,treatedwithendoscopichaemostasisandbloodtrans-
fusion, aspirin was stopped and substituted for clopidogrel.
One month later an US conﬁrmed the renal neoplasm
(diameters approximately 12cm and irregular burden, with
a central necrotic area); for this reason he was adminis-
tered sunitinib, scheduled for a nine-cycle therapy. Surgical
treatment of the neoplasm was not considered in this
patient because of his high bleeding tendency. After a few
weeks, because of a rectal bleeding, he was admitted in an
emergency care unit: clopidogrel was stopped and laboratory
tests revealed prolonged aPTT, normal platelet counts and
anaemia. In the suspect of AHA, he was treated with rFVII
(90µg/kg i.v. bolus) with complete resolution of bleeding.
Further investigations of the coagulation abnormality were
n o tp e r f o r m e da tt h a tt i m e .
Because of the leg haematoma and lower back pain,
he was ﬁnally referred to our hospital. On admission,
coagulationtestsconﬁrmedtheprolongedaPTT(92seconds,
normal 26–44), not corrected at mixing test, with normal
prothrombin time (PT), international normalized ratio
(INR), and bleeding time (Ivy, 3 minutes, normal values
<7). Haemoglobin level was 9.4g/L and platelet count was
260 × 109/L. Abdominal US showed the presence of right
iliopsoas and gluteal haematomas. A CT scan conﬁrmed
the presence of the renal neoplasm and of the muscle
bleeds. FVIII:C was 9.3% and the FVIII:C inhibitor titre
was 3.5BU/mL. AHA was, therefore, diagnosed. He was
treated with a single rFVII 90µg/kg i.v. bolus with a
reduction of back pain and with an apparent cessation
of bleeding (stable haemoglobin level and dimensions of
haematomas at US follow-up). Immunosuppressive therapy
with prednisone 1mg/kg/day was started the day after
admission. About two weeks later, aPTT was still prolonged,
FVIII:C was 29%, and FVIII:C inhibitor titre was 2.1BU/ml,
thus cyclophosphamide 1mg/Kg/day was added. Four weeks
later, normalization of aPTT was obtained, inhibitor was
0.2BU/ml, haemoglobin levels progressively improved and
steroid therapy was continued for the following 4 weeks
and then gradually discontinued. Cyclophosphamide was
stopped6weeksaftertheeradicationoftheFVIII:Cinhibitor.
Since a sustained response was obtained, according to recent
recommendations [5], aPTT, FVIII:C, and FVIII inhibitor
were evaluated monthly, in the ﬁrst six months, then every
3 months in the following six months and every six months
thereafter.Duringatwo-yearfollow-upthepatientpresented
no further haemorrhage. Three months after the discharge,
he started low dose aspirin (100mg/day) for secondary
prevention of his coronary heart disease. Sunitinib was
continued. The neoplasm was assumed as the cause of AHA
in this elderly patient.
Case 2. A 68-year-old man presented with multiple spon-
taneous haematomas (gluteal, neck, and lower limbs), in
the absence of personal or family history of bleeding or
clotting disorders. His past medical history included type
2 diabetes mellitus, arterial hypertension, prostatic hyper-
trophy, psoriasis, and arthrosis. At that time he was taking
nonsteroidal anti-inﬂammatory drugs (NSAIDs) because of
back pain. A previous haematoma of the left arm, after an
eﬀort, occurred approximately 6 weeks before the admission,
when he also was on NSAID treatment; one month later
he reported a gluteal and leg haematomas immediately afterCurrent Gerontology and Geriatrics Research 3
Table 2: AHA: diﬀerential diagnosis in the elderly.
(1) Mild-moderate hereditary haemophilia diagnosed after
the age of 60 years [16]
(2) Lupus anticoagulant
(3) Bleeding complications of anticoagulant treatments
(4) Trauma
(5) Abuse of NSAIDs
(6) Other acquired bleeding disorders (acquired von
Willebrand disease, acquired platelet dysfunctions,
uremia, and liver cirrhosis)
an intramuscular NSAID injection because of his recurrent
back pain. A week later he presented with a wide neck
haematoma unsuccessfully treated with tranexamic acid,
therefore he was referred to our hospital. On admission,
laboratory investigations revealed anaemia (haemoglobin
8.2g/L)andnormalplateletcount(219×109/L).Coagulation
tests showed a moderately prolonged aPTT (54.8 seconds)
with normal PT and INR. APTT was not modiﬁed after
mixingtest,lupusanticoagulant(LAC)wasnegative,FVIII:C
was 16%, and FVIII inhibitor was 2.3BU/ml, leading to
diagnosing AHA. Factor IX, factor X, factor XI, factor XII,
and von Willebrand Factor were normal, bleeding time was
7 minutes and 30 seconds.
The day after the admission, the patient had dyspnoea
and haemoglobin levels further decreased (7.0g/dl), thus
transfusions with packed red blood cells were required
(2 Units). A CT scan conﬁrmed the presence of a large
haematoma in the neck. Because of the reduction of
haemoglobin levels and the harmful site of bleeding, a
90µg/kg rFVIIa i.v. bolus was administered and repeated
after 3 hours with an apparent resolution of bleeding (stable
haemoglobin values). Concomitantly, immunosuppressive
therapy with prednisone 1mg/kg/day was started. As spon-
taneous bruising of the upper limbs occurred and aPTT was
still prolonged, cyclophosphamide 1.5mg/kg/day was added.
Clinical and laboratory features improved in the following
two weeks, with a progressive normalization of the aPTT
and the eradication of the FVIII inhibitor (undetectable
inhibitor, normal FVIII:C). Since inhibitor eradication was
obtained, cyclophosphamide was discontinued after 4 weeks
and prednisone gradually stopped after 2 months. During a
three-year follow-up, no further bleeding occurred. Psoriatic
arthritis was diagnosed few months after the withdrawal of
immunosuppressive treatment. This underlying immuno-
logic disorder was therefore associated with AHA in this
patient, in whom bleeding tendency had been triggered by
NSAIDs.
Case 3. A 87-year-old woman presented with persistent
rectal bleeding and large ecchymoses. Her past medical
history included Hodgkin’s disease about 10 years earlier, in
apparent long-term remission, and type 2 diabetes mellitus.
On admission, laboratory investigations revealed severe
anaemia (haemoglobin 6.7g/L) and mild reduction of
platelet count (125 × 109/L). Coagulation tests showed a
prolonged aPTT (99 seconds) not corrected at mixing test
and normal PT and INR. LAC was negative, FVIII:C was
16%, and FVIII inhibitor was 33.2BU/ml, conﬁrming the
diagnosis of AHA. Transfusions with packed red blood
cells were required due to anaemia and the persistent
haemorrhagic tendency, and a rFVIIa 90µg/kg i.v. bolus was
administered,andrepeatedafterthreehours,withtemporary
cessation of bleeding. Prednisone was immediately started
at doses of 1mg/kg/day. One week later, she presented
again decrease in haemoglobin level, with FVIII:C and
FVIII inhibitor unchanged. The patient received packed
red blood cells and another rFVIIa i.v. bolus. A CT scan
revealed a large dorsal muscle haematoma, with no signs
of recurrence of Hodgkin’s disease. Further investigations
led to exclude other malignant or autoimmune diseases.
Therefore this case was assumed to be idiopathic AHA.
During admission, she experienced other episodes of rectal
bleeding with signiﬁcant reduction of haemoglobin levels.
In each occasion, she received single rFVIIa i.v. bolus,
achieving haemostasis. After three weeks of prednisone
treatment, aPTT was normalized and FVIII:C was 105%,
withnegativeFVIIIinhibitor.However,thepatientpresented
septic fever and dyspnoea, with clinical signs of pneumonia
and pleural eﬀusion, and positive haemoculture for Staphy-
lococcusAureo.Inspiteoftreatmentwithimipenem(500mg
thrice a day) and teicoplanine (200mg once daily), the
patient presented a rapid worsening of haemodynamic and
respiratory condition, requiring orotracheal intubation and
intensive care treatment. In this patient AHA was not fatal
because of bleeding, but because of septic complications due
to immunosuppressive therapy.
3. Discussion
AHAisararebutlife-threateningbleedingdisorder,typically
occurring in the elderly. According to recent data, the
incidence in subjects aged <65yrs is 0.28 per million per
year, but increases up to 5.97 in those aged 65–85yrs and
to 16.6 in individuals older than 85 yrs [2]. On the whole,
more than 80% of diagnosed patients are aged >60yrs [2,
3]. Moreover, these data are likely to be underestimated
becauseofundiagnosedandunreportedcases.Therefore,the
impact of AHA is not negligible in elderly patients, in whom
the diﬀerential diagnosis with other age-correlated bleeding
conditions should be also taken into account (Table 2)[ 16].
The diagnosis of AHA should be considered in any
elderly patient who presents with bleeding and an isolated
prolonged aPTT. The mixing test is a simple assay able to
reveal the presence of inhibitors of coagulation [9]. Indeed,
a prolonged aPTT may be attributable to coagulation factor
deﬁciencies, lupus anticoagulant (LAC), or heparin therapy
(Table 3). The presence of LAC may also be associated
with a prolonged aPTT that is not corrected with normal
plasma, but in this case no bleeding tendency is shown.
Quantitative coagulation factor assays should be also per-
formed which reveal a reduced level of FVIII:C in AHA.
Milder reduction of factor IX, XI, and XII plasma levels
may also be shown; increasing dilutions of patient plasma
with normal plasma lead to diluting the autoantibody and4 Current Gerontology and Geriatrics Research
Table 3: Diagnostic tests in AHA in the elderly (see Huth-Kuhne
et al., modiﬁed [5]).
(1) Mixing test: prolongation of the aPTT in a mixture of
patient and normal plasma after 1-2h incubation
compared to an immediate mix is typical of FVIII
autoantibodies.
(2) Clotting factor measurement: patients should have FVIII,
IX, X, XI, XII levels measured; an isolated low FVIII level
is suggestive of AHA.
(3) Quantiﬁcation of the inhibitor titer: Bethesda assay, the test
should be repeated to conﬁrm the presence of the inhibitor.
to normalizing activities of factors other than FVIII, which
remains inhibited even by the diluted speciﬁc autoantibody.
These tests also enable the detection of more rare cases due
to antibodies against coagulation factors other than FVIII
[6]. The diagnosis is then conﬁrmed by a Bethesda (or its
Nijmegen modiﬁcation) positive assay. It is noteworthy to
remark that the mixing test may be easily carried out in all
laboratories and allows the identiﬁcation of patients who
require further investigations at a specialized centre.
When AHA is diagnosed, the possible coexistence of
an underlying disease responsible for this immunologic
complication should be suspected and intensively searched
for. In particular, in elderly patients AHA is often sec-
ondary to haematologic or solid malignancy or drugs (e.g.,
antibiotics, phenytoin, methyldopa, interferon, ﬂudarabine,
and clopidogrel) [6, 13]. However, about half of the cases
are apparently idiopathic although in some patients an
underlying disorder may be diagnosed long after the onset
of the bleeding abnormality [6, 17], as reported in patient
no. 2.
Our case reports conﬁrm the complexity of the man-
agement of AHA in elderly patients, in whom the clinical
picture is complicated by comorbidities and concomitant
drug intake. The latter may facilitate bleeding complications,
as occurred in patients no. 1 and 2, or delay the diagnosis,
when antiplatelet or anticoagulant drugs are administered.
The coexistence in AHA patients, in particular in the
elderly, of overt cardiovascular/thromboembolic diseases
(see patient no. 1) and/or risk factors such as diabetes
mellitus, neoplasm, arterial hypertension, high body mass
index, requiring antithrombotic treatment, represents a
challenging issue in this setting. The occurrence of severe
bleeding leads to the withdrawal of such treatments and
in many cases to the administration of bypassing agents
(APCCs, rFVIIa), with possible increase of thromboembolic
risk. This risk is further enhanced by the reduced mobility
due to hospitalization or muscle bleeding or by activation of
coagulation induced during sepsis. Thus an accurate balance
of bleeding and thrombotic risk should be carefully taken
into account when these patients are treated for the bleeding
complications, in terms of doses and duration of bypassing
agent administration. Presently, however, evidence of rFVIIa
and aPCC thrombogenicity is limited, therefore according
to recent recommendations, bypassing agents should not be
considered contraindicated in the presence of severe or life-
threatening bleed and also in patients at thromboembolic
risk [1–6]. In elderly patients, however, especially in those
presenting posttreatment high FVIII:C levels, an adequate
prolongedprophylaxiswithantithromboticagents,following
inhibitor eradication, should be considered (see Case 1).
An early and appropriate therapeutic approach is crucial
for a favourable outcome, which also depends on the treat-
ment and the prognosis of any possible concomitant disease
or triggering condition [6, 8, 13]. Bleeding complications are
fatal in 10%–20% of the cases, but the overall mortality in
AHA patients is also higher, in particular, in elderly patients
and over the ﬁrst weeks after the onset of symptoms, because
of the underlying associated diseases, diagnostic delays,
inadequatetreatmentofacutebleeds,bleedingcomplications
during invasive procedures for controlling hemorrhages, or
adverse events of treatment (infections, sepsis on immuno-
suppressive therapy, see Case 3)[ 3–6].
Therefore, patients with AHA should be managed by a
hemophilia center with laboratory and clinical experience
in this setting, in particular because of the complexity
of treatment. Immunosuppressive regimens in the elderly
should aim to eradicate the inhibitor as rapidly as possi-
ble, reducing the time of exposure to the side eﬀects of
immunosuppressive therapy [5]. Prednisone (1mg/Kg/day
for 4–6 weeks) remains the ﬁrst-line treatment, alone or
in combination with cyclophosphamide (1.5–2mg/Kg/day).
The latter should be administered for a maximum of six
weeks, and the risk/beneﬁt ratio of immunosuppressive
therapy should be taken into account for each elderly patient
individually [5]. Other approaches should be considered for
refractorypatients.Inparticular,rituximabmaybesuggested
when ﬁrst-line immunosuppressive treatment fails or is
contraindicated [5, 10–14].
Despite the lack of deﬁnite conclusions on the optimal
hemostatic and inhibitor eradicating approaches, a series of
eﬀectiveoptionsispresentlyavailable,givingtheopportunity
of tailoring the treatment of this rare but severe disease, even
in the “fragile” elderly patients.
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